p53 positively regulates the expression of cancer stem cell marker CD133 in HCT116 colon cancer cells

Chen,Xia; Guan,Hua; Liu,Xiao‑Dan; Xie,Da‑Fei; Wang,Yu; Ma,Teng; Huang,Bo; Zhou,Ping‑Kun

doi:10.3892/ol.2018.8619

p53 positively regulates the expression of cancer stem cell marker CD133 in HCT116 colon cancer cells

Authors:
- Xia Chen
- Hua Guan
- Xiao‑Dan Liu
- Da‑Fei Xie
- Yu Wang
- Teng Ma
- Bo Huang
- Ping‑Kun Zhou
View Affiliations

Affiliations: Institute for Environmental Medicine and Radiation Hygiene, School of Public Health, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Radiation Toxicology and Oncology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China
Published online on: May 2, 2018 https://doi.org/10.3892/ol.2018.8619
Pages: 431-438

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colon cancer stem cells (CSCs), which are highly capable of self‑renewal and proliferation, are involved in colon tumorigenesis and response to therapy. CD133 is considered the most robust surface marker for colorectal cancer stem cells. Although the TP53 gene is frequently mutated in colon cancer, it remains not fully understood whether and how tumor protein p53 (p53) is associated with CD133 expression in colon cancer cells. In the present study, the expression of the CSC biomarker CD133 was investigated in terms of p53 status in colorectal carcinoma HCT116 cells. p53 wild‑type HCT116 (HCT116 p53+/+) and depleted HCT116 (HCT116 p53‑/‑) cells were used throughout this study. Cells carrying the CSC biomarkers CD133 and CD44 were examined by flow cytometry. A dual‑luciferase reporter assay was employed to further confirm the transcriptional regulation of the CD133 promoter by p53. The results demonstrated that there was a significant difference in the % of CD133‑positive cells between the HCT116 p53+/+ cell line (84.84±0.05%) and the HCT116 p53‑/‑ cell line (4.13±0.02%). The mRNA expression levels of CD133 in HCT116 p53+/+ cells were also significantly higher compared with HCT116 p53‑/‑ cells. Knockdown of p53 by specific small interfering RNA greatly reduced the expression of CD133 in HCT116 p53+/+ cells. Transcription factor binding site analysis indicated that there are several p53 binding elements in the CD133 promoter region. A dual‑luciferase reporter assay further demonstrated the transcriptional activation of CD133 promoter by p53. In conclusion, these results suggest that p53 positively regulates the expression of CSC marker CD133 in the HCT116 human colon colorectal cancer cell line. p53 may be involved in the initiation and maintenance of colorectal cancer stem cells through regulating the expression of CD133.

View Figures

View References

1	Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kerr D: Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer. 3:615–622. 2003. View Article : Google Scholar : PubMed/NCBI
3	Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
4	Puglisi MA, Tesori V, Lattanzi W, Gasbarrini GB and Gasbarrini A: Colon cancer stem cells: Controversies and perspectives. World J Gastroenterol. 19:2997–3006. 2013. View Article : Google Scholar : PubMed/NCBI
5	Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T and Jung A: The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 219:427–434. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hongo K, Kazama S, Sunami E, Tsuno NH, Takahashi K, Nagawa H and Kitayama J: Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. Med oncol. 29:2849–2857. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ying X, Wu J, Meng X, Zuo Y, Xia Q, Chen J, Feng Y, Liu R, Li L and Huang W: AC133 expression associated with poor prognosis in stage II colorectal cancer. Med Oncol. 30:3562013. View Article : Google Scholar : PubMed/NCBI
8	Kai K, Nagano O, Sugihara E, Arima Y, Sampetrean O, Ishimoto T, Nakanishi M, Ueno NT, Iwase H and Saya H: Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci. 100:2275–2282. 2009. View Article : Google Scholar : PubMed/NCBI
9	Li XL, Zhou J, Chen ZR and Chng WJ: P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 21:84–93. 2015. View Article : Google Scholar : PubMed/NCBI
10	Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R and Vodicka P: Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis. 27:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hall EH, Schoenbach KH and Beebe SJ: Nanosecond pulsed electric fields induce apoptosis in p53-wildtype and p53-null HCT116 colon carcinoma cells. Apoptosis. 12:1721–1731. 2007. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Wang B, Xiao Z and Ren EC: Redefining the p53 response element. Proc Natl Acad Sci USA. 106:14373–14378. 2009. View Article : Google Scholar : PubMed/NCBI
14	Schuster-Bockler B, Schultz J and Rahmann S: HMM Logos for visualization of protein families. BMC Bioinformatics. 5:72004. View Article : Google Scholar : PubMed/NCBI
15	Marinescu VD, Kohane IS and Riva A: MAPPER: A search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics. 6:792005. View Article : Google Scholar : PubMed/NCBI
16	Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
17	O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007. View Article : Google Scholar : PubMed/NCBI
18	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
19	Wu Y and Wu PY: CD133 as a marker for cancer stem cells: Progresses and concerns. Stem Cells Dev. 18:1127–1134. 2009. View Article : Google Scholar : PubMed/NCBI
20	Chen KL, Pan F, Jiang H, Chen JF, Pei L, Xie FW and Liang HJ: Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44 (high) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis. 28:751–763. 2011. View Article : Google Scholar : PubMed/NCBI
21	Yang ZL, Zheng Q, Yan J, Pan Y and Wang ZG: Upregulated CD133 expression in tumorigenesis of colon cancer cells. World J Gastroenterol. 17:932–937. 2011. View Article : Google Scholar : PubMed/NCBI
22	Chantret I, Barbat A, Dussaulx E, Brattain MG and Zweibaum A: Epithelial polarity, villin expression and enterocytic differentiation of cultured human colon carcinoma cells: A survey of twenty cell lines. Cancer Res. 48:1936–1942. 1988.PubMed/NCBI
23	Konishi H, Asano N, Imatani A, Kimura O, Kondo Y, Jin X, Kanno T, Hatta W, Ara N, Asanuma K, et al: Notch1 directly induced CD133 expression in human diffuse type gastric cancers. Oncotarget. 30:56598–56607. 2016.
24	Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, et al: mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 69:7160–7164. 2009. View Article : Google Scholar : PubMed/NCBI
25	Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, et al: HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 71:4640–4652. 2011. View Article : Google Scholar : PubMed/NCBI
26	Won C, Kim BH, Yi EH, Choi KJ, Kim EK, Jeong JM, Lee JH, Jang JJ, Yoon JH, Jeong WI, et al: Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology. 62:1160–1173. 2015. View Article : Google Scholar : PubMed/NCBI
27	Mak AB, Nixon AM and Moffat J: The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. Cancer Res. 72:1929–1934. 2012. View Article : Google Scholar : PubMed/NCBI
28	Iida H, Suzuki M, Goitsuka R and Ueno H: Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79. 2012.PubMed/NCBI
29	Zhang L, Li H, Ge C, Li M, Zhao FY, Hou HL, Zhu MX, Tian H, Zhang LX, Chen TY, et al: Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma. Oncotarget. 5:10621–10635. 2014.PubMed/NCBI
30	Ohnishi S, Maehara O, Nakagawa K, Kameya A, Otaki K, Fujita H, Higashi R, Takagi K, Asaka M, Sakamoto N, et al: hypoxia-inducible factors activate CD133 promoter through ETS family transcription factors. PLoS One. 8:e662552013. View Article : Google Scholar : PubMed/NCBI
31	Min KJ, So KA, Ouh YT, Hong JH and Lee JK: The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers. J Ovarian Res. 5:282012. View Article : Google Scholar : PubMed/NCBI
32	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
33	Puca F, Colamaio M, Federico A, Gemei M, Tosti N, Bastos AU, Del Vecchio L, Pece S, Battista S and Fusco A: HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget. 5:3234–3245. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zeilstra J, Joosten SP, Vermeulen L, Koster J, Medema JP, Versteeg R, Spaargaren M and Pals ST: CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. PLoS One. 8:e728492013. View Article : Google Scholar : PubMed/NCBI
35	Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, Park JH, Kwon SH, You JS, Nam SW, et al: Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 6:e19642015. View Article : Google Scholar : PubMed/NCBI
36	Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et al: CD133 expression is not restricted to stem cells and both CD133⁺ and CD133⁻ metastatic colon cancer cells initiate tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
37	Kawamoto H, Yuasa T, Kubota Y, Seita M, Sasamoto H, Shahid JM, Hayashi T, Nakahara H, Hassan R, Iwamuro M, et al: Characteristics of CD133(+) human colon cancer SW620 cells. Cell Transplant. 19:857–864. 2010. View Article : Google Scholar : PubMed/NCBI
38	Rassouli FB, Matin MM and Saeinasab M: Cancer stem cells in human digestive tract malignancies. Tumour Biol. 37:7–21. 2016. View Article : Google Scholar : PubMed/NCBI
39	Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, Denissov S, Stunnenberg HG and Lohrum M: Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res. 36:3639–3654. 2008. View Article : Google Scholar : PubMed/NCBI
40	Hoh J, Jin S, Parrado T, Edington J, Levine AJ and Ott J: The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci USA. 99:8467–8472. 2002. View Article : Google Scholar : PubMed/NCBI
41	Gowrisankar S and Jegga AG: Regression based predictor for p53 transactivation. BMC Bioinformatics. 10:2152009. View Article : Google Scholar : PubMed/NCBI
42	Ma B, Pan Y, Zheng J, Levine AJ and Nussinov R: Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets. Nucleic Acids Res. 35:2986–3001. 2007. View Article : Google Scholar : PubMed/NCBI
43	Veprintsev DB and Fersht AR: Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res. 36:1589–1598. 2008. View Article : Google Scholar : PubMed/NCBI
44	Tebaldi T, Zaccara S, Alessandrini F, Bisio A, Ciribilli Y and Inga A: Whole-genome cartography of p53 response elements ranked on transactivation potential. BMC Genomics. 16:4642015. View Article : Google Scholar : PubMed/NCBI
45	Botcheva K and McCorkle SR: Cell context dependent p53 genome-wide binding patterns and enrichment at repeats. PLoS One. 9:e1134922014. View Article : Google Scholar : PubMed/NCBI
46	Williams K, Christensen J, Rappsilber J, Nielsen AL, Johansen JV and Helin K: The histone lysine demethylase JMJD3/KDM6B is recruited to p53 bound promoters and enhancer elements in a p53 dependent manner. PLoS One. 9:e965452014. View Article : Google Scholar : PubMed/NCBI
47	Zhao Q, Zhou H, Liu Q, Cao Y, Wang G, Hu A, Ruan L, Wang S, Bo Q, Chen W, et al: Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models. Oncotarget. 7:47431–47443. 2016.PubMed/NCBI
48	Thanan R, Pairojkul C, Pinlaor S, Khuntikeo N, Wongkham C, Sripa B, Ma N, Vaeteewoottacharn K, Furukawa A, Kobayashi H, et al: Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Radic Biol Med. 65:1464–1472. 2013. View Article : Google Scholar : PubMed/NCBI
49	Le H, Zeng F, Xu L, Liu X and Huang Y: The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Mol Med Rep. 8:1511–1518. 2013. View Article : Google Scholar : PubMed/NCBI
50	Zhuang HW, Mo TT, Hou WJ, Xiong GX, Zhu XL, Fu QL and Wen WP: Biological characteristics of CD133(+) cells in nasopharyngeal carcinoma. Oncol Rep. 30:57–63. 2013. View Article : Google Scholar : PubMed/NCBI
51	Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, Chen JP, Zhou ZG, Mo XM and Hu JK: Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: A systematic review. PLoS One. 8:e591542013. View Article : Google Scholar : PubMed/NCBI
52	Kim K, Ro JY, Kim S and Cho YM: Expression of stem-cell markers OCT-4 and CD133: Important prognostic factors in papillary renal cell carcinoma. Human Pathol. 43:2109–2116. 2012. View Article : Google Scholar